SAN DIEGO, May 18, 2016 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, today announced that
the Company will host its fiscal third quarter 2016 financial
results conference call on Thursday, June
9 at 1:15 PM PT/4:15 PM ET. To listen to the conference call,
please dial (877) 731-1960 and use conference ID number: 4148915.
An archived version of the presentation will be available for 90
days on the "Investors" section of OncoSec's website:
ir.oncosec.com/events.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse™,
for the treatment of cancer. ImmunoPulse™ is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various skin
cancers as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently
in clinical development for several indications, including
metastatic melanoma and triple-negative breast cancer. In addition
to ImmunoPulse™ IL-12, the Company is also identifying and
developing new immune-targeting agents for use with the
ImmunoPulse™ platform. For more information, please visit
www.oncosec.com.
Contact
Mary
Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-host-third-quarter-financial-results-conference-call-on-june-9-2016-300270311.html
SOURCE OncoSec Medical Incorporated